Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matt Devalaraja

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Kidney360|April 4, 2022
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKDKristen L Nowak, Rahul Kakkar, Matt Devalaraja, et al.
Journal of Clinical Medicine|April 19, 2019
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts StudyBelinda Spoto, Rahul Kakkar, Larry Lo, et al.
Journal of the American Society of Nephrology : JASN|December 4, 2020
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialPablo E Pergola, Matt Devalaraja, Steven Fishbane, et al.
The Journal of Investigative Dermatology|February 16, 2016
Use of a Canine Model of Atopic Dermatitis to Investigate the Efficacy of a CCR4 Antagonist in Allergen-Induced Skin Inflammation in a Randomized StudyClare Murray, Kim Ahrens, Matt Devalaraja, et al.
Journal of the American Heart Association|September 14, 2022
Race, Interleukin-6, <i>TMPRSS6</i> Genotype, and Cardiovascular Disease in Patients With Chronic Kidney DiseaseIan R Barrows, Matt Devalaraja, Rahul Kakkar, et al.
Journal of Clinical Pharmacology|May 10, 2011
Population pharmacokinetics and exposure-response of albinterferon alfa-2bMatthew M Riggs, Timothy T Bergsma, James A Rogers, et al.
Lancet (London, England)|May 20, 2021
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialPaul M Ridker, Matt Devalaraja, Florian M M Baeres, et al.
The New England Journal of Medicine|July 10, 2009
Raxibacumab for the treatment of inhalational anthraxThi-Sau Migone, G Mani Subramanian, John Zhong, et al.
Science Translational Medicine|January 31, 2020
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglyceridesAnna Wolska, Larry Lo, Denis O Sviridov, et al.
European Journal of Heart Failure|May 16, 2019
The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF studyGeorge Markousis-Mavrogenis, Jasper Tromp, Wouter Ouwerkerk, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Kidney360|April 4, 2022
A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKDKristen L Nowak, Rahul Kakkar, Matt Devalaraja, et al.
Journal of Clinical Medicine|April 19, 2019
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts StudyBelinda Spoto, Rahul Kakkar, Larry Lo, et al.
Journal of the American Society of Nephrology : JASN|December 4, 2020
Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialPablo E Pergola, Matt Devalaraja, Steven Fishbane, et al.
The Journal of Investigative Dermatology|February 16, 2016
Use of a Canine Model of Atopic Dermatitis to Investigate the Efficacy of a CCR4 Antagonist in Allergen-Induced Skin Inflammation in a Randomized StudyClare Murray, Kim Ahrens, Matt Devalaraja, et al.
Journal of the American Heart Association|September 14, 2022
Race, Interleukin-6, <i>TMPRSS6</i> Genotype, and Cardiovascular Disease in Patients With Chronic Kidney DiseaseIan R Barrows, Matt Devalaraja, Rahul Kakkar, et al.
Journal of Clinical Pharmacology|May 10, 2011
Population pharmacokinetics and exposure-response of albinterferon alfa-2bMatthew M Riggs, Timothy T Bergsma, James A Rogers, et al.
Lancet (London, England)|May 20, 2021
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trialPaul M Ridker, Matt Devalaraja, Florian M M Baeres, et al.
The New England Journal of Medicine|July 10, 2009
Raxibacumab for the treatment of inhalational anthraxThi-Sau Migone, G Mani Subramanian, John Zhong, et al.
Science Translational Medicine|January 31, 2020
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglyceridesAnna Wolska, Larry Lo, Denis O Sviridov, et al.
European Journal of Heart Failure|May 16, 2019
The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF studyGeorge Markousis-Mavrogenis, Jasper Tromp, Wouter Ouwerkerk, et al.
Pageof 1